{"id":"NCT03924986","sponsor":"BeiGene","briefTitle":"Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)","officialTitle":"A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Compare the Efficacy and Safety of Tislelizumab (BGB-A317) Combined With Gemcitabine Plus Cisplatin Versus Placebo Combined With Gemcitabine Plus Cisplatin as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-03-27","primaryCompletion":"2021-03-26","completion":"2023-12-08","firstPosted":"2019-04-23","resultsPosted":"2025-01-31","lastUpdate":"2025-01-31"},"enrollment":263,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Recurrent or Metastatic Nasopharyngeal Cancer"],"interventions":[{"type":"DRUG","name":"Tislelizumab","otherNames":["BGB-A317"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Gemcitabine","otherNames":[]},{"type":"DRUG","name":"Cisplatin","otherNames":[]}],"arms":[{"label":"Arm A: Tislelizumab + Gemcitabine + Cisplatin","type":"EXPERIMENTAL"},{"label":"Arm B: Placebo + Gemcitabine + Cisplatin","type":"PLACEBO_COMPARATOR"}],"summary":"This study was designed to compare the efficacy and safety of tislelizumab (BGB-A317) combined with gemcitabine plus cisplatin versus placebo combined with gemcitabine plus cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal cancer.","primaryOutcome":{"measure":"Progression-free Survival as Assessed by the Independent Review Committee (IRC)","timeFrame":"Through the study interim data analysis cutoff date of March 26th, 2021 (maximum time on study follow-up was 23 months)","effectByArm":[{"arm":"Arm A: Tislelizumab + Gemcitabine + Cisplatin","deltaMin":9.2,"sd":null},{"arm":"Arm B: Placebo + Gemcitabine + Cisplatin","deltaMin":7.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":37,"countries":["China","Taiwan","Thailand"]},"refs":{"pmids":["38671587","37207654"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":47,"n":133},"commonTop":["Anaemia","Nausea","White blood cell count decreased","Neutrophil count decreased","Platelet count decreased"]}}